ArticleJournal of inflammation research2025
Integrated Early CRP Kinetics and Plasma EBV DNA Clearance as Prognostic Biomarkers in De Novo Metastatic Nasopharyngeal Carcinoma Treated with First-Line Chemoimmunotherapy.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The evolution of EBV DNA as a biomarker in nasopharyngeal carcinoma immunotherapy: a bibliometric and knowledge mapping analysis.Virology journal · 2026Article
- Harnessing the immune microenvironment: advances in nasopharyngeal carcinoma immunotherapy.Cell death discovery · 2026Review
- The application of grayscale quantitative analysis in the differential diagnosis of necrosis between cervical lymph node metastases in nasopharyngeal carcinoma and tuberculous lymphadenitis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigates the predictive value of early C-reactive protein (CRP) kinetics in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving first-line chemotherapy combined with anti-PD-1 mAbs (first-line chemoimmunotherapy). Patients and Methods: Patients were categorized into three groups based on early CRP kinetics within one and three months after the start of immunotherapy: (1) CRP flare-responders, with CRP levels rising to more than double the baseline within one month and subsequently falling below baseline within three months; (2) CRP non-flare-responders, with CRP levels decreasing by more than 30% within three months without initial flare; (3) CRP non-responders, with no significant CRP changes. Associations with objective response rate (ORR), and progression-free survival (PFS) were evaluated. Results: The multicenter study included 149 patients with dmNPC (median follow-up: 22 months). The cohort comprised 39 (26.2%) CRP flare-responders, 76 (51%) CRP non-flare-responders, and 34 (22.8%) CRP non-responders. CRP flare-responders and non-flare-responders were combined into CRP responders, showing significantly improved ORR (94.8% vs 79.4%, P=0.009) and prolonged median PFS (20 vs 13 months, P=0.006) compared to CRP non-responders. Multivariable analysis identified early CRP kinetics as an independent prognostic factor for PFS (HR=2.688, 95% CI: 1.484-4.868, P<0.001). In subgroup analysis, patients with undetectable EBV DNA after three immunotherapy cycles showed higher median PFS among CRP responders compared to non-responders (28 vs 21 months, P=0.014), whereas no significant difference was observed in patients with detectable EBV DNA levels (13 vs 8 months, P=0.142). Conclusion: CRP responders are associated with improved survival outcomes, particularly in patients achieving early EBV DNA clearance. Early CRP kinetics combined with early plasma EBV DNA clearance may be predictive of survival outcomes in dmNPC patients receiving first-line chemoimmunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.